To address this hypothesis, we used an animal model of type 1 diabetes, which was treated with a selective A2AR antagonist, SCH 58261, by an intravitreal injection every week, for four weeks, starting one month after the onset of diabetes. This evidence concerns the gene ADORA2A and diabetes mellitus.